The development of animal genetic modification systems has made it possible to use protein production systems to produce biopharmaceuticals in large quantities (e.g., cattle milk and from poultry eggs). There are transgenic rabbits, sheep, goats and cows that produce biopharmaceuticals in their milk [1, 2]. The first drug produced in transgenic animals, antithrombin III in goat milk, was approved for use by the European Medicines Agency in 2006 and by the FDA in 2009 [3]. However, there are limitations to the use of large mammals as bioreactors. They have long gestation periods. They require large amounts of space and feed, which can make industrial expansion difficult and expensive. Purification of recombinant protein from milk can also be difficult because of the high lipid and other protein content [4].